14 ch. des Aulx
1228 Plan-Les-Ouates, ch
+41 (22) 83971-41
Genentech Initiates First-in-Human Study with NovImmune's Anti-IL17 Antibody
Jack Barbut, CEO, commented "With the compound entering man, NovImmune is gratified to see Genentech's continued commitment to the anti-IL-17 program. This news creates an additional milestone as this is the fifth NovImmune therapeutic antibody to enter clinical development; a significant achievement for a small biotech company."
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.